|

ETN101 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Etnova Therapeutics Corp.1

Indications

  • Liver Disease1
  • Advanced Hepatocellular Carcinoma1
  • Liver Cancer1
  • Hepatocellular Carcinoma1
  • Cancer1

Other1 trial

A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.